NEWRON PHARMACEUT. EO-20 (NP5) — Financial Flexibility Index
NEWRON PHARMACEUT. EO-20 (NP5) has a Financial Flexibility Index of 0.63x as of December 2025. Free cash flow of €32.40 Million (operating CF €32.35 Million minus capex €48.00K) represents 1% of total liabilities (€51.19 Million). Check NEWRON PHARMACEUT. EO-20 (NP5) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NEWRON PHARMACEUT. EO-20 Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for NEWRON PHARMACEUT. EO-20 across 5 annual periods. For the full cash flow conversion analysis, see NEWRON PHARMACEUT. EO-20 cash conversion from operations.
Annual Financial Flexibility Index for NEWRON PHARMACEUT. EO-20 (2021–2025)
Year-by-year free cash flow to debt coverage for NEWRON PHARMACEUT. EO-20. Explore NP5 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.63x | €32.40 Million | €32.35 Million | €51.19 Million | ▲ +324.6% |
| 2024 | -0.28x | €-17.60 Million | €-17.61 Million | €62.45 Million | ▼ -55.2% |
| 2023 | -0.18x | €-10.13 Million | €-10.14 Million | €55.77 Million | ▲ +16.0% |
| 2022 | -0.22x | €-11.07 Million | €-11.09 Million | €51.23 Million | ▲ +10.3% |
| 2021 | -0.24x | €-11.43 Million | €-11.45 Million | €47.38 Million | — |